Therefore, targeting the expression or functional modulation of TPM2, PDLIM7, or YAP1 may serve as a promising therapeutic strategy to reduce PCa proliferation and prevent the progression of CRPC. This evidence concerns the gene YAP1 and posterior cortical atrophy.